Trial results for the IMpower010 study (NCT02486718) investigating atezolizumab (Tecentriq) in patients with non-small cell lung cancer were posted on ClinicalTrials.gov on 2025-03-30. The study showed that atezolizumab extended median disease-free survival (DFS) to 68.5 months in the PD-L1 positive Stage II-IIIA population, compared to 37.3 months for best supportive care.
Background
The IMpower010 study investigated atezolizumab as an adjuvant treatment in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and chemotherapy.
Trial design
The IMpower010 study (NCT02486718) was a Phase 3, global, multicenter, open-label, randomized study that enrolled 1280 participants. The trial compared atezolizumab treatment to best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant cisplatin-based chemotherapy. Participants were randomized in a 1:1 ratio to receive either atezolizumab for 16 cycles or BSC.
Key results
The trial results showed differences in disease-free survival (DFS) and disease-free rates between the atezolizumab and best supportive care (BSC) arms across various populations.
- For Disease-Free Survival (DFS) in the Intent-to-treat (ITT) Population, the median DFS was 65.6 months for the atezolizumab group compared to 47.8 months for the BSC group. The Hazard Ratio (HR) was 0.848 (95% Confidence Interval: 0.71 to 1.013), with a Log Rank p-value of 0.0683.
- In the All Randomized Stage II-IIIA Population, the median DFS was 57.4 months for atezolizumab versus 40.8 months for BSC. The Hazard Ratio (HR) was 0.83 (95% Confidence Interval: 0.691 to 0.998).
- For DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation within the Stage II-IIIA Population, median DFS was 68.5 months for atezolizumab compared to 37.3 months for BSC. The Hazard Ratio (HR) was 0.704 (95% Confidence Interval: 0.545 to 0.91).
Regarding Disease-free Rate at Year 3:
- In the ITT Population, the rate was 61.43% for atezolizumab versus 55.45% for BSC, with a difference in event-free rates of 5.98 (95% Confidence Interval: -0.28 to 12.23).
- In the All Randomized Stage II-IIIA Population, the rate was 59.30% for atezolizumab versus 52.64% for BSC, with a difference in event-free rates of 6.65 (95% Confidence Interval: -0.06 to 13.36).
- In the PD-L1 (SP263 ≥ 1% TC) Subpopulation within the Stage II-IIIA Population, the rate was 62.72% for atezolizumab versus 52.05% for BSC, with a difference in event-free rates of 10.67 (95% Confidence Interval: 1.56 to 19.79).
What this means
The results from the IMpower010 trial indicate that atezolizumab as an adjuvant therapy extends disease-free survival in patients with resected Stage IB-IIIA non-small cell lung cancer following chemotherapy. The most pronounced benefit was observed in the PD-L1 positive Stage II-IIIA population, where atezolizumab significantly improved median DFS and the 3-year disease-free rate compared to best supportive care. These findings suggest atezolizumab could be an important treatment option for improving outcomes in this specific patient group.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT02486718, titled "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]," were posted on 2025-03-30 on clinicaltrials.gov.